| Objective:This research seeks to evaluate the clinical effects and safety of Danlou tablets in the patients with dyslipidemia after PCI for CHD(Phlegm and blood stasis syndrome),by the changes of Blood stasis syndrome score,TCM main syndrome score and lipid levels.Methods:A total of 132 patients with dyslipidemia after PCI for CHD(Phlegm and blood stasis syndrome)was selected from Xiyuan Hospital of Chinese Academy of Traditional Chinese Medicine,and divided into two groups according to their willingness to take Chinese medicine,treatment group and control group.The control group(66 cases,fall off 6 cases)was treated with conventional western medicine for 12 months,and the treatment group(66 cases,fall off 5 cases)was treated with Danlou tablets(5 pieces,tid)on the basis of conventional western medicine for 6 months and follow-up for 6 months.A total of 121 patients was observed in the end.Blood samples were taken before treatment,6 months after treatment and 12 months after treatment,and blood lipid levels,liver and kidney function,blood routine,coagulation and other safety indicators were recorded.The scores of blood stasis syndrome and main symptoms of TCM were recorded before treatment,3 months after treatment,6 months after treatment and 12 months after treatment.After the treatment,the improvement of blood lipid level,blood stasis syndrome score and TCM main symptom score in the two groups were analyzed,and the efficacy evaluation and safety analysis were conducted.Results:1.Effect analysisLipid levels:There was no significant difference in blood lipid level between the two groups before treatment(P>0.05).At each time point of treatment,the difference between the two groups was statistically significant(P<0.05).There was no significant difference between the two groups at 3 and 6 months after treatment(P>0.05),and there was significant difference between the two groups at 12 months after treatment(P<0.05).After 12 months of treatment,the effective rate of the treatament group was 91.8%,and that of the control group was 76.7%.And the difference in the effective rate between the two groups was statistically significant(P<0.05).Blood stasis syndrome score:There was no statistically significant difference in blood stasis syndrome score between the two groups before treatment(P>0.05).At each time point of treatment,the scores of blood stasis syndrome in the two groups were significantly different from those before treatment(P<0.05).At 3 months and 6 months after treatment,there was no statistically significant difference in blood stasis score between the two groups(P>0.05),and there was statistically significant difference in blood stasis score between the two groups after 12 months of treatment(P<0.05).TCM main symptom score:There was no statistically significant difference in TCM score between the two groups before treatment(P>0.05).At each time point of treatment,the scores of main symptoms of TCM in the two groups were significantly different from those before treatment(P<0.05).At 3 months and 6 months of treatment,there was no statistically significant difference in TCM syndrome score between the two groups(P>0.05),while at 12 months of treatment,there was statistically significant difference in TCM syndrome score between the two groups(P<0.05).2.SafetyThere was no statistically significant difference in safety indexes between the two groups before and after treatment(P>0.05).No adverse events occurred during the test.Conclusion:1.Danlou tablets can effectively improve the blood lipid level after PCI in patients with CHD with phlegm and blood stasis syndrome.2.Danlou tablets can effectively improve the blood stasis syndrome score and TCM main syndromes score of patients with CHD after PCI.3.The safety of Danlou tablets is obvious,and there was no obvious abnormality in liver and kidney function,blood routine,coagulation and other safety indexes during the test,and no adverse events occurred. |
PDF Full Text Request